Amylyx Pharmaceuticals Inc (AMLX) — Capital Reinvestment Ratio

Latest as of December 2023: 0.03x

Amylyx Pharmaceuticals Inc (AMLX) has a Capital Reinvestment Ratio of 0.03x as of December 2023, meaning it reinvests 0% of its operating cash flow ($13.55 Million) in capital expenditures ($356.00K). See AMLX equity financing ratio to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.03x
Capex / Operating Cash Flow

Operating Cash Flow

$13.55 Million
USD

Capital Expenditures

$356.00K
USD

Data as of

Dec 2023
Most recent filing

Amylyx Pharmaceuticals Inc Capital Reinvestment Ratio (2023–2023)

This chart tracks Amylyx Pharmaceuticals Inc's Capital Reinvestment Ratio across 1 annual periods. Check how aggressively does Amylyx Pharmaceuticals Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Amylyx Pharmaceuticals Inc (2023–2023)

Year-by-year Capital Reinvestment Ratio for Amylyx Pharmaceuticals Inc from 2023 to 2023. For live market cap and broader valuation context, see how much is Amylyx Pharmaceuticals Inc worth.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2023 0.10x $11.92 Million $1.24 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow